Login to Your Account

Other News To Note

Tuesday, November 13, 2012
• Morphotek Inc., of Exton, Pa., a subsidiary of Eisai Inc., said it has been granted FDA orphan drug designation for its investigational cancer drug, amatuximab (MORAb-009), a chimeric IgG1 antibody that targets a cell surface glycoprotein, mesothelin.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription